Leuko has raised $5.0M in total across 1 funding round.
Leuko's investors include Good Growth Capital.
Leuko is a medical device startup developing PointCheck, the first noninvasive white blood cell (WBC) monitoring device for cancer patients and others at risk of neutropenia.[1][3][4][5] It serves chemotherapy patients and immunosuppressed individuals by enabling fast, at-home testing via optics and AI, eliminating blood draws to make monitoring easier, more accessible, and cost-effective than lab-based methods.[1][3][5] The device images blood cells in finger capillaries to detect low WBC levels, signaling elevated infection risk and enabling timely interventions, with strong growth momentum shown by a $5 million Series A in 2021 from investors like HTH VC and Good Growth Capital to fund clinical trials and regulatory approval.[1][4]
Leuko spun out from MIT and the Madrid-MIT M+Visión Consortium in 2017, founded by Carlos Castro-Gonzalez, Aurelien Bourquard, Ian Butterworth, and Alvaro Sanchez-Ferro—research fellows in a biomedical innovation program who identified the unmet need for noninvasive WBC monitoring in chemotherapy patients.[1][2][4] Castro-Gonzalez, with a PhD in biomedical engineering and MIT M+Vision fellowship experience, led the invention of PointCheck alongside the team's expertise in optics, AI, medical imaging, and clinical studies.[1][2][4] Early traction included securing funding, clinical collaborations with centers like Boston Medical Center and MD Anderson, and awards recognizing their innovation in point-of-care tech.[1][2][4]
Leuko rides the wave of point-of-care diagnostics and AI-driven medtech, addressing remote patient monitoring trends accelerated by pandemics and rising cancer prevalence.[1][5] Timing aligns with demand for home-based care to cut healthcare costs and improve outcomes—frequent WBC checks prevent infections, a major chemotherapy complication, amid shortages in lab infrastructure globally.[1][3][5] Market forces like regulatory pushes for noninvasive tools (e.g., FDA pathways) and investor interest in healthtech favor Leuko, positioning it to influence decentralized cancer care by reducing clinic visits and enabling data-driven treatments.[1][4]
Leuko is poised for regulatory clearance and market entry post-Series A-funded trials, potentially launching PointCheck by late 2020s to transform neutropenia management.[1][4] Trends like AI personalization in oncology and telehealth expansion will amplify its impact, evolving its role from investigational device to standard in-home tool for broader immunosuppressed populations.[5] As medtech shifts to patient-centric, noninvasive solutions, Leuko's MIT roots and clinical momentum signal enduring influence in accessible diagnostics, fulfilling its promise to ease cancer care burdens.[1][4]
Leuko has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Series A in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $5.0M Series A | Good Growth Capital |
